PARP1 and ovarian carcinoma: PARP inhibitors, such as olaparib, rucaparib, and niraparib, have proven effective as single agents in treating patients with recurrent ovarian cancer and as maintenance therapy in patients who responded to platinum-based therapy [11, 14–18].